Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

CC-4047 (Pomalidomide) for Graft vs. Host Disease
A Phase 2, Open-Label, Single-Arm, Pilot Study of Safety and Efficacy of CC-4047 (Pomalidomide) in Patients With Advanced Chronic Graft-Versus-Host Disease Developing After Allogeneic Hematological Stem Cell Transplantation
Status: Enrolling
Updated:  1/28/2016
Washington University School of Medicine
mi
from
St. Louis, MO
CC-4047 (Pomalidomide) for Graft vs. Host Disease
A Phase 2, Open-Label, Single-Arm, Pilot Study of Safety and Efficacy of CC-4047 (Pomalidomide) in Patients With Advanced Chronic Graft-Versus-Host Disease Developing After Allogeneic Hematological Stem Cell Transplantation
Status: Enrolling
Updated: 1/28/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation of Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  1/28/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation of Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 1/28/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Status: Enrolling
Updated:  1/28/2016
Indiana University Cancer Center
mi
from
Indianapolis, IN
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Status: Enrolling
Updated: 1/28/2016
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD
Use of a Transdermal Patch to Noninvasively Monitor Inflammatory Biomarkers of Acute and Chronic Skin GVHD
Status: Enrolling
Updated:  1/28/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD
Use of a Transdermal Patch to Noninvasively Monitor Inflammatory Biomarkers of Acute and Chronic Skin GVHD
Status: Enrolling
Updated: 1/28/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
The Scripps Research Institute
mi
from
LaJolla, CA
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
The Scripps Research Institute
mi
from
LaJolla, CA
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
University of Maryland Medical Center
mi
from
Baltimore, MD
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
Syosset Hospital
mi
from
Lake Success, NY
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
Syosset Hospital
mi
from
Lake Success, NY
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated:  2/1/2016
Rhode Island Hospital
mi
from
Providence, RI
CryoSpray Ablation (TM) GI Patient Registry
CryoSpray Ablation (TM) GI Patient Registry
Status: Enrolling
Updated: 2/1/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Little Rock VA Medical Center
mi
from
Little Rock, AR
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Little Rock VA Medical Center
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
West Los Angeles VA Medical Center
mi
from
Los Angeles, CA
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
West Los Angeles VA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
San Francisco VA Medical Center
mi
from
San Francisco, CA
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
San Francisco VA Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Eastern Colorado Health Care System
mi
from
Denver, CO
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Eastern Colorado Health Care System
mi
from
Denver, CO
Click here to add this to my saved trials
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
West Haven VA Medical Center
mi
from
West Haven, CT
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
West Haven VA Medical Center
mi
from
West Haven, CT
Click here to add this to my saved trials
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Tampa VA Medical Center
mi
from
Tampa, FL
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Tampa VA Medical Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Atlanta VA Medical Center
mi
from
Atlanta, GA
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Atlanta VA Medical Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
VA Boston Healthcare System
mi
from
Jamaica Plain, MA
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
VA Boston Healthcare System
mi
from
Jamaica Plain, MA
Click here to add this to my saved trials
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Kansas City VA Medical Center
mi
from
Kansas City, MO
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Kansas City VA Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Pittsburgh VA Medical Center
mi
from
Pittsburgh, PA
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Pittsburgh VA Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Central Arkansas Veterans Healthcare System
mi
from
Little Rock, AR
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Central Arkansas Veterans Healthcare System
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
West Los Angeles VA Medical Center
mi
from
Los Angeles, CA
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
West Los Angeles VA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Click here to add this to my saved trials
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
VA Boston Healthcare System
mi
from
Jamaica Plain, MA
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
VA Boston Healthcare System
mi
from
Jamaica Plain, MA
Click here to add this to my saved trials
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Kansas City VA Medical Center
mi
from
Kansas City, MO
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Kansas City VA Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Pittsburgh VA Medical Center
mi
from
Pittsburgh, PA
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Pittsburgh VA Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  2/1/2016
Houston VA Medical Center
mi
from
Houston, TX
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 2/1/2016
Houston VA Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma
Status: Enrolling
Updated:  2/1/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma
Status: Enrolling
Updated: 2/1/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated:  2/2/2016
OHSU Cancer Institute-Southern Region
mi
from
Medford, OR
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated: 2/2/2016
OHSU Cancer Institute-Southern Region
mi
from
Medford, OR
Click here to add this to my saved trials
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated:  2/2/2016
VA Puget Sound Health Care System
mi
from
Seattle, WA
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated: 2/2/2016
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated:  2/2/2016
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated: 2/2/2016
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated:  2/2/2016
LDS Hospital
mi
from
Salt Lake City, UT
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated: 2/2/2016
LDS Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated:  2/2/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated: 2/2/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated:  2/2/2016
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated: 2/2/2016
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated:  2/2/2016
Medizinische Univ Klinik Koln
mi
from
Koln,
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Status: Enrolling
Updated: 2/2/2016
Medizinische Univ Klinik Koln
mi
from
Koln,
Click here to add this to my saved trials
Efficacy and Safety of IL-11 in DDAVP Unresponsive
Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP
Status: Enrolling
Updated:  2/3/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Efficacy and Safety of IL-11 in DDAVP Unresponsive
Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP
Status: Enrolling
Updated: 2/3/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
Status: Enrolling
Updated:  2/3/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
Status: Enrolling
Updated: 2/3/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
Status: Enrolling
Updated:  2/4/2016
Shands Cancer Hospital at the University of Florida
mi
from
Gainesville, FL
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
Status: Enrolling
Updated: 2/4/2016
Shands Cancer Hospital at the University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated:  2/5/2016
Sarcoma Oncology Center
mi
from
Santa Monica, CA
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated: 2/5/2016
Sarcoma Oncology Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated:  2/5/2016
Howard University
mi
from
Washington,
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated: 2/5/2016
Howard University
mi
from
Washington,
Click here to add this to my saved trials
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated:  2/5/2016
Montgomery Cancer Center
mi
from
Mount Sterling, KY
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated: 2/5/2016
Montgomery Cancer Center
mi
from
Mount Sterling, KY
Click here to add this to my saved trials
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated:  2/5/2016
Gabrail Cancer Center
mi
from
Canton, OH
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated: 2/5/2016
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated:  2/5/2016
Gabrail Cancer Center Research
mi
from
Dover, OH
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated: 2/5/2016
Gabrail Cancer Center Research
mi
from
Dover, OH
Click here to add this to my saved trials
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated:  2/5/2016
Signal Point Hematology/Oncology
mi
from
Middletown, OH
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated: 2/5/2016
Signal Point Hematology/Oncology
mi
from
Middletown, OH
Click here to add this to my saved trials
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated:  2/5/2016
Flavio Castaneda M.D.
mi
from
Laredo, TX
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated: 2/5/2016
Flavio Castaneda M.D.
mi
from
Laredo, TX
Click here to add this to my saved trials
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated:  2/5/2016
South Texas Research Alliance
mi
from
Laredo, TX
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy
Status: Enrolling
Updated: 2/5/2016
South Texas Research Alliance
mi
from
Laredo, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
PMK Medical Group, Inc., dba Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
PMK Medical Group, Inc., dba Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Rocky Mountain Cancer Centers - Aurora
mi
from
Aurora, CO
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Rocky Mountain Cancer Centers - Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials